News
Videos
Conferences
Events
Resources
Subscribe

Opinion|Videos|May 29, 2024

Ibrutinib-Based Treatment Clinical Trial Updates

Author(s)Yuliya P.L Linhares, MD, Josie Montegaard, MSN, AGPCNP-BC

Turning the focus to ibrutinib-based therapy, Yuliya Linhares, MD, gives an overview of the RESONATE study.

Episodes in this series

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 1 Understanding a CLL Diagnosis

Yuliya P.L Linhares, MD, an expert on CLL

EP. 2 Diagnostic Tests in CLL

Video 3 - "Goals of Treatment for Patients With CLL"

EP. 3 Goals of Treatment for Patients With CLL

Video 4 - "Current First-Line Treatment Options in CLL"

EP. 4 Current First-Line Treatment Options in CLL

Yuliya P.L Linhares, MD, an expert on CLL

EP. 5 Factors That Guide CLL Treatment Decisions

Josie Montegaard, MSN, AGPCNP-BC, an expert on CLL

EP. 6 What to Expect from Treatment

Video 7 - "Overview of Efficacy and Safety Data for Current CLL Treatment Options"

EP. 7 Overview of Efficacy and Safety Data for Current CLL Treatment Options

Video 8 - "Acalabrutinib-Based Treatment Clinical Trial Updates"

EP. 8 Acalabrutinib-Based Treatment Clinical Trial Updates

Yuliya P.L Linhares, MD, an expert on CLL

EP. 9 Venetoclax-Based Treatment Clinical Trial Updates

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 10 Zanubrutinib-Based Treatment Clinical Trial Updates

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 11 Ibrutinib-Based Treatment Clinical Trial Updates

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 12 Newer Combinations for the Treatment of CLL

Josie Montegaard, MSN, AGPCNP-BC, an expert on CLL

EP. 13 What to Know Before Starting Your CLL Treatment

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 14 An Overview of Potential Treatment Adverse Effects

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 15 Treatment Decisions in R/R CLL

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 16 Shared Decision-Making and Supportive Care in the CLL Treatment Journey

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 17 Optimizing Overall Health During CLL Management

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL

EP. 18 Getting the Most From Your CLL Care Team

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Jaypirca therapy improved progression-free survival versus bendamustine plus Rituxan a phase 3 trial for untreated CLL/SLL: © stock.adobe.com.

Jaypirca Significantly Improves PFS Outcomes in Untreated CLL/SLL

BySabrina Serani

December 9th 2025

In a direct comparison, Jaypirca matched Imbruvica in response and suggested a progression-free survival benefit for patients with CLL/SLL.

Updated Data Reinforce Treatment With Jaypirca in CLL/SLL

ByJason Broderick

December 8th 2025

CLL

Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit

ByJason M Broderick

December 7th 2025

fda approved

FDA Approves Jaypirca for Relapsed/Refractory CLL or SLL

December 3rd 2025

Image of andy.

A Season to be Grateful as a Cancer Survivor

ByAndy Winnegar

November 17th 2025

Trending on CURE

FDA Approves Enhertu Plus Perjeta in Advanced HER2+ Breast Cancer

Acupuncture Improves Cognitive Function in Breast Cancer Survivors

Light the Night and Survivorship: The Importance of Remembrance

FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer

Accepting That You Are Changed by Cancer

© 2025 MJH Life Sciences^®

All rights reserved.